(Q28299036)

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

21 January 2018

1 reference

Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.

21 January 2018

1 reference

Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent

21 January 2018

1 reference

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

21 January 2018

1 reference

HSP110-HER2/neu Chaperone Complex Vaccine Induces Protective Immunity Against Spontaneous Mammary Tumors in HER-2/neu Transgenic Mice

21 January 2018

1 reference

Vaccines: past, present and future

21 January 2018

1 reference

Cancer prevention: a global perspective

31 March 2020

1 reference

Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls

31 March 2020

1 reference

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

31 March 2020

1 reference

Epidemiology and prevention of breast cancer

31 March 2020

1 reference

Chemoprevention: an essential approach to controlling cancer

31 March 2020

1 reference

Overview of the main outcomes in breast-cancer prevention trials

31 March 2020

1 reference

Animal models of tumor immunity, immunotherapy and cancer vaccines

31 March 2020

1 reference

Cancer vaccines: between the idea and the reality

31 March 2020

1 reference

Cancer immunotherapy: moving beyond current vaccines

31 March 2020

1 reference

Cellular immunity for cancer chemoimmunotherapy--an overview

31 March 2020

1 reference

Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12.

31 March 2020

1 reference

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes

31 March 2020

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

31 March 2020

1 reference

Stuck in the MUC on the long and winding road

31 March 2020

1 reference

Effect of interleukin 12 on tumor induction by 3-methylcholanthrene

31 March 2020

1 reference

The promise of genetically engineered mice for cancer prevention studies

31 March 2020

1 reference

Vaccine development: baring the 'dirty little secret'

31 March 2020

1 reference

Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice

31 March 2020

1 reference

Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity

31 March 2020

1 reference

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

31 March 2020

1 reference

Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.

31 March 2020

1 reference

Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions

31 March 2020

1 reference

Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice

31 March 2020

1 reference

Immunological inhibition of carcinogenesis

31 March 2020

1 reference

Immunological prevention of a multigene cancer syndrome

31 March 2020

1 reference

Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein

31 March 2020

1 reference

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

31 March 2020

1 reference

Selective estrogen-receptor modulators for primary prevention of breast cancer

31 March 2020

1 reference

Aromatase inhibitors for breast cancer prevention

31 March 2020

1 reference

The role of models in understanding CD8+ T-cell memory

31 March 2020

1 reference

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

31 March 2020

1 reference

Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

31 March 2020

1 reference

The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity

31 March 2020

1 reference

Immunobiology of her-2/neu transgenic mice.

31 March 2020

1 reference

Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice

31 March 2020

1 reference

Prevention of breast tumour development in vivo by downregulation of the p185neu receptor

31 March 2020

1 reference

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function

31 March 2020

1 reference

Fatal attraction: tumors beckon regulatory T cells

31 March 2020

1 reference

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

31 March 2020

1 reference

Eradication of established tumors by CD8+ T cell adoptive immunotherapy

31 March 2020

1 reference

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells

31 March 2020

1 reference

Derangement of immune responses by myeloid suppressor cells

31 March 2020

1 reference

Cancer genes and the pathways they control

31 March 2020

1 reference

The immunobiology of cancer immunosurveillance and immunoediting

31 March 2020

1 reference

T-cell-antigen recognition and the immunological synapse

31 March 2020

1 reference

MHC antigens and tumor escape from immune surveillance

31 March 2020

1 reference

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.

31 March 2020

1 reference

Premalignant lesions as targets for cancer vaccines

31 March 2020

1 reference

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas

31 March 2020

1 reference

p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma

31 March 2020

1 reference

Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

31 March 2020

1 reference

Cancer immunoprevention: tracking down persistent tumor antigens

31 March 2020

1 reference

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

31 March 2020

1 reference

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines.

31 March 2020

1 reference

Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice.

31 March 2020

1 reference

Vaccines in the public eye.

31 March 2020

1 reference

Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy

31 March 2020

1 reference

CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice

31 March 2020

1 reference

Immunity to cancer through immune recognition of altered self: studies with melanoma

31 March 2020

1 reference

A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.

31 March 2020

1 reference

Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation

31 March 2020

1 reference

The advent of the "unpatients'.

31 March 2020

1 reference

Design of effective immunotherapy for human autoimmunity

31 March 2020

1 reference

Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages

31 March 2020

1 reference

What's wrong with our cancer models?

31 March 2020

1 reference

Immunotherapy and immunoprevention of cancer: where do we stand?

31 March 2020

1 reference

New target antigens for cancer immunoprevention

31 March 2020

1 reference

Untangling the ErbB signalling network

31 March 2020

1 reference

Immunization against IGF-I prevents increases in protein synthesis in diabetic rats after resistance exercise.

31 March 2020

1 reference

Insulin-like growth factor-1 (IGF-1)-derived peptide protects against diabetes in NOD mice

31 March 2020

1 reference

Vaccination against tumor neovascularization: Promise and reality

31 March 2020

1 reference

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

31 March 2020

1 reference

Cancer vaccines: pessimism in check

31 March 2020

1 reference

Genetic immunization against neu/erbB2 transgenic breast cancer

31 March 2020

1 reference

A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors

31 March 2020

1 reference

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

31 March 2020

1 reference

Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity

31 March 2020

1 reference

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

31 March 2020

1 reference

Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine

31 March 2020

1 reference

Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice

31 March 2020

1 reference

Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin.

31 March 2020

1 reference

Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization

31 March 2020

1 reference

Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells

31 March 2020

1 reference

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice

31 March 2020

1 reference

Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer

31 March 2020

1 reference

Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis

31 March 2020

1 reference

Identification of tumour-associated T-cell epitopes for vaccine development

31 March 2020

1 reference

B cells inhibit induction of T cell-dependent tumor immunity.

31 March 2020

1 reference